Form D · Pharmaceuticals
Zynerba Pharmeceuticals, Inc.
Radnor, PA · CIK 0001621443
Offering snapshot reported Oct 9, 2014 · SEC filing
- Reported sold
- $7.31M Offering amount: $13M
- Investors reported
- 30 Form D · investor count
- Minimum accepted
- $0 Reported outside-investor minimum
- First sale
- Sep 24, 2014 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Oct 9, 2014 | Initial | $7,309,180 | No comparison | 30 | SEC filing |
Offering details
- Securities
- Equity, Option to acquire, Security to be acquired
- Exemptions
- 06b
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $0
- Finders' fees
- $0
- Form D file number
- 021-226158
The Placement Agent was reimbursed for expenses incurred in connection with the offering and received cash and stock for services to the company including financial advisory, management consulting and executive recruitment.
Sales compensation recipients
Scroll to see all columns →
| Recipient | CRD | Associated broker-dealer |
|---|---|---|
| Broadband Capital Management, LLC | 48001 |
Source: Form D, filed Oct 9, 2014. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Armando Anindo | Director, Executive |
| Steven Gailar | Director |
| Suzanne Hanlon | Executive |
| Terri B. Sebree | Executive |
| Philip Wagenheim | Director |
Issuer details
Industry: Pharmaceuticals (See others in industry)
Address:
170 N. Radnor Chester Road Suite 350
Radnor, PA, 19087
Radnor, PA, 19087